ClinicaliQ Trial Snapshot
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2) — Active Not Recruiting • Phase III • Neurology • NCT04437511.
- Donanemab slows cognitive decline in early Alzheimer's disease; follow-up study monitors long-term safety and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up. Conditions: Alzheimer Disease Interventions: Donanemab, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 1736 participants